Serum proteins modulate lipopolysaccharide and lipoteichoic acid-induced activation and contribute to the clinical outcome of sepsis

Virulence

Volumn 3, Issue 2, 2012, Pages 136-145

  Triantafilou, Martha ^a   Mouratis, Marios Angelos ^a   Lepper, Philipp M ^b   Haston, Rowenna Mitch ^a   Baldwin, Fiona ^c   Lowes, Sarah ^c   Elrahman Ahmed, Mohamed Abd ^d   Schumann, Christian ^e   Boyd, Owen ^c   Triantafilou, Kathy ^a  

^a CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^b SAARLAND UNIVERSITY   (Germany)

^c ROYAL SUSSEX COUNTY HOSPITAL   (United Kingdom)

^d AIN SHAMS UNIVERSITY   (Egypt)

^e UNIVERSITY OF ULM   (Germany)

Author keywords

LPS; LTA; Sepsis; Serum proteins

Indexed keywords

ALBUMIN; APOLIPOPROTEIN; HEMOGLOBIN; HOLOTRANSFERRIN; LIPOPOLYSACCHARIDE; LIPOTEICHOIC ACID; LOW DENSITY LIPOPROTEIN; PLASMA PROTEIN; TRANSFERRIN; UNCLASSIFIED DRUG;

ADULT; AFFINITY CHROMATOGRAPHY; AGED; ARTICLE; CONTROLLED STUDY; CRITICALLY ILL PATIENT; FEMALE; HUMAN; INFLAMMATION; INNATE IMMUNITY; MALE; MASS SPECTROMETRY; PROTEIN BINDING; PROTEIN ISOLATION; PROTEOMICS; SEPSIS;

BACTERIA (MICROORGANISMS);

EID: 84862890677     PISSN: 21505594     EISSN: 21505608     Source Type: Journal    
DOI: 10.4161/viru.19077     Document Type: Article

References (36)

1. Poltorak A, Ricciardi-Castagnoli P, Citterio S, Beutler B. Physical contact between lipopolysaccharide and Toll-like receptor 4 revealed by genetic complementation. Proc Natl Acad Sci USA 2000; 97:2163-7; PMID:10681462; http://dx.doi.org/10.1073/pnas.040565397
2. Qureshi ST, Lariviere L, Leveque G, Clermont S, Moore KJ, Gros P, et al. Endotoxin-tolerant mice have mutations in toll-like receptor 4 (TLR4). J Exp Med 1999; 189:615-25; PMID:9989976; http://dx.doi.org/ 10.1084/jem.189.4.615
3. Schwandner R, Dziarski R, Wesche H, Rothe M, Kirschning CJ. Peptidoglycan-and Lipoteichoic acidinduced cell activation is mediated by Toll-like receptor J Biol Chem 1999; 274:17406-9; PMID:10364168; http://dx.doi.org/10.1074/jbc.274.25.17406
4. Triantafilou M, Brandenburg K, Kusumoto S, Fukase K, Mackie A, Seydel U, et al. Combinational clustering of receptors following stimulation by bacterial products determines LPS responses. Biochem J 2004; 381: 527-36; PMID:15040785; http://dx.doi.org/10.1042/ BJ20040172
5. Triantafilou M, Lepper PM, Briault CD, Ahmed AM, Dmochowski JM, Schumann C, et al. Chemokine receptor 4 (CXCR4) is part of the lipopolysaccharide "sensing apparatus". Eur J Immunol 2008; 38:192-203; PMID:18081034; http://dx.doi.org/10.1002/eji. 200636821
6. Ulevitch RJ, Johnston AR. The modification of biophysical and endotoxin properties of bacterial lipopolysaccharides by serum. J Clin Invest 1978; 62:1313-24; PMID:372234; http://dx.doi.org/10.1172/JCI109252
7. Van Lenten BJ, Fogelman AM, Haberland ME, Edwards PA. The role of lipoproteins and receptor-mediated endocytosis in the transport of bacterial lipopolysaccharide. Proc Natl Acad Sci USA 1986; 83:2704-8; PMID: 3517876; http://dx.doi.org/10.1073/pnas.83.8.2704
8. Harris HW, Grunfeld C, Feingold KR, Rapp JH. Human very low density lipoproteins and chylomicrons can protect against endotoxin-induced death in mice. J Clin Invest 1990; 86:696-702; PMID:2394827; http:// dx.doi.org/10.1172/JCI114765
9. Miyazawa K, Mentel C, Lu L, Morrison DC, Broxmeyer HE. Lactoferrin-lipopolysaccharide interactions. J Immunol 1991; 146:723-9; PMID:1702815
10. Fletcher J. The effect of iron and transferrin on the killing of Escherichia coli in fresh medium. Immunology 1971; 20:493-500; PMID:4994865
11. Berger D, Berger H. Quantitation of the endotoxinbinding capacity of human transferrin. Bact Endotoxins 1988;115-124.
12. Roth RI, Kaca W, Levin J. Hemoglobin, a newly recognized binding protein for bacterial endotoxins (LPS). Prog Clin Biol Res 1994; 388:161-72; PMID:7831356
13. Roth R, Kaca W. Toxicity of haemoglobin solutions: Haemoglobin is a lipopolysaccharide (LPS) binding protein which enhances LPS biological activity. Art Cells. Blood Subs and Immob Biotech 1994; 22:387-98; http://dx.doi.org/10.3109/10731199409117869
14. Grunfeld C, Marshall M, Shigenaga JK, Moser AH, Tobias P, Feingold KR. Lipoproteins inhibit macrophage activation by lipoteichoic acid. J Lipid Res 1999; 40:245-52; PMID:9925653
15. Munford RS, Hall CL, Dietschy JM. Binding of Salmonella typhimurium lipopolysaccharide to rat highdensity lipoproteins. Infect Immun 1981; 34:835-43; PMID:7037642
16. Ulevitch RJ, Johnston AR, Meinstein DB. New function of high density lipoproteins. J Clin Invest 1981; 67:827-37; PMID:7204557; http://dx.doi.org/10. 1172/JCI110100
17. Kitchens RL, Wolfbauer G, Albers JJ, Munford RS. Plasma lipoproteins promote the release of bacterial lipopolysaccharide from the monocyte cell surface. J Biol Chem 1999; 274:34116-22; PMID:10567381; http://dx.doi.org/10.1074/jbc.274.48.34116
18. Sprong T, Netea MG, van der Ley PT, Verver-Jansen TJG, Jacobs LEH, Stalenhoef A, et al. Human lipoproteins have divergent neutralizing effects on E. Coli LPS, N. meningitidis LPS, and complete Gram-negative bacteria. J Lipid Res 2004; 45:742-9; PMID:14754910; http://dx.doi.org/10.1194/jlr.M300453-JLR200
19. Gordon BR, Parker TS, Levine DM, Saal SD, Wang JC, Sloan BJ, et al. Relationship of hypolipidemia to cytokine concentrations and outcomes in critically ill surgical patients. Crit Care Med 2001; 29: 1563-8; PMID:11505128; http://dx.doi.org/10.1097/ 00003246-200108000-00011
20. Thabut D, Tazi KA, Bonnefont-Rousselot D, Aller M, Farges O, Guimont MC, et al. High-density lipoprotein administration attenuates liver proinflammatory response, restores liver endothelial nitric oxide synthase activity, and lowers portal pressure in cirrhotic rats. Hepatology 2007; 46:1893-906; PMID:17918268; http://dx.doi.org/10.1002/hep.21875
21. Flegel WA, Baumstark MW, Weinstock C, Berg A, Northoff H. Prevention of endotoxin-induced cytokine release by human low-and high-density lipoproteins and by apolipoprotein A-I. Infect Immun 1993; 61: 5140-6; PMID:8225591
22. Hubsch AP, Powell FS, Lerch PG, Doran JE. A reconstituted, apolipoprotein A-1 containing lipoprotein reduces tumour necrosis factor release and attenuates shock in endotoxemic rabbits. Circ Shock 1993; 40:14-23; PMID:8324886
23. de Bont N, Netea MG, Demacker PNM, Verschueren I, Kullberg BJ, Van Dijk KW, et al. Apolipoprotein E knock-out mice are highly susceptible to endotoxemia and Klebsiella pneumoniae infection. J Lipid Res 1999; 40:680-5; PMID:10191292
24. Recalde D, Ostos MA, Badell E, Garcia-Otin AL, Pidoux J, Castro G, et al. Human Apolipoprotein A-IV reduces secretion of pro-inflammatory cytokines and atherosclerotic effects of a chronic infection mimicked by lipopolysaccharide. Arterioscler Thromb Vasc Biol 2004; 24:756-61; PMID:14751811; http://dx.doi.org/ 10.1161/01.ATV.0000119353.03690.22
25. Berbée JF, Havekes LM, Rensen PC. Apolipoproteins modulate the inflammatory response to lipopolysaccharide. J Endotoxin Res 2005; 11:97-103; PMID: 15949136
26. de Haas CJC, van Leeuwen HJ, Verhoef J, van Kessel KPM, van Strijp JAP. Analysis of lipopolysaccharide (LPS)-binding characteristics of serum components using gel filtration of FITC-labelled LPS. J Immunol Methods 2000; 242:79-89; PMID:10986391; http:// dx.doi.org/10.1016/S0022-1759(00)00207-6
27. Dziarski R. Cell bound albumin is the 70 kDa peptidoglycan-, lipopolysaccharide, and lipoteichoic acid-binding protein on lymphocytes and macrophages. J Biol Chem 1994; 269:20431-6; PMID:8051139
28. Mueller M, Stamme C, Draing C, Hartung T, Seydel U, Schromm AB. Cell activation of human macrophages by lipoteichoic acid is strongly attenuated by lipopolysaccharide-binding protein. J Biol Chem 2006; 281:31448-56; PMID:16928689; http://dx.doi.org/10. 1074/jbc.M605966200
29. Manthey CL, Vogel SN. Elimination of trace endotoxin protein from rough chemotype LPS. J Endotoxin Res 1994; 1:84-90.
30. Tapping RI, Akashi S, Miyake K, Godowski PJ, Tobias PS. Toll-like receptor 4, but not toll-like receptor 2, is a signalling receptor for Escherichia and Salmonella Lipopolysaccharides. J Immunol 2000; 165:5780-7; PMID:11067937
31. Hirschfeld M, Ma Y, Weis JH, Vogel SN, Weis JJ. Repurification of lipopolysaccharide eliminates signalling through both human and murine toll-like receptor 2. J Immunol 2000; 165:618-22; PMID:10878331
32. Morath S, Geyer A, Spreitzer I, Hermann C, Hartung T. Structural decomposition and heterogeneity of commercial lipoteichoic acid preparations. Infect Immun 2002; 70:938-44; PMID:11796629; http://dx.doi.org/ 10.1128/IAI.70.2.938-944.2002
33. Troelstra A, Antal-Szalmas P, De Graaf-Miltenburg LA, Weersink AJ, Verhoef J, Van kessel KP, et al. Saturable CD14-dependent binding of fluorescein-labelled lipopolysaccharide to human monocytes. Infect Immun 1997; 65:2272-7; PMID:9169763
34. Triantafilou M, Triantafilou K, Fernandez N. Rough and smooth forms of fluorescein-labelled bacterial endotoxin exhibit CD14/LBP dependent and independent binding that is influenced by endotoxin concentartion. Eur J Biochem 2000; 267:2218-26; PMID:10759844; http://dx.doi.org/10.1046/j.1432-1327.2000.01222.x
35. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 SCCM/ESICM/ACCP/ATS/ SIS International Sepsis Definitions Conference. Crit Care Med 2003; 31:1250-6; PMID:12682500; http:// dx.doi.org/10.1097/01.CCM.0000050454.01978.3B
36. Triantafilou K, Triantafilou M, Dedrick RLA. CD14-independent LPS receptor cluster. Nat Immunol 2001; 2:338-45; PMID:11276205; http://dx.doi.org/10. 1038/86342